Harvard Management CO Inc Nu Cana PLC Transaction History

Harvard Management CO Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$1.95 - $2.85 $754,891 - $1.1 Million	-387,124 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$2.7 - $5.04 $1.63 Million - $3.05 Million	-605,281 Reduced 60.99%	387,124 $1.07 Million
Q1 2021 May 07, 2021	SELL	$4.38 - $7.0 $3 Million - $4.8 Million	-685,834 Reduced 40.87%	992,405 $4.95 Million
Q4 2020 Feb 12, 2021	SELL	$4.4 - $5.59 $2.82 Million - $3.59 Million	-641,541 Reduced 27.66%	1,678,239 $7.54 Million
Q3 2020 Nov 13, 2020	SELL	$4.57 - $6.48 $2.6 Million - $3.68 Million	-568,531 Reduced 19.68%	2,319,780 $12.1 Million
Q2 2020 Aug 14, 2020	SELL	$4.87 - $7.37 $111,036 - $168,036	-22,800 Reduced 0.78%	2,888,311 $15.6 Million
Q4 2019 Feb 14, 2020	BUY	$5.55 - $8.48 $16.2 Million - $24.7 Million	2,911,111 New	2,911,111 $17.3 Million

3.33M

Ticker NCNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,196,000
Market Cap $59M
Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...

Get notified when there are updates to the investment portfolio of Harvard Management CO Inc, based on Form 13F filings with the SEC.

Stay updated on Harvard Management CO Inc with notifications on news.